MCL Literature Feed

A case of TP53-mutated, indolent non-nodal MCL suggests this high-risk marker may not mandate immediate therapy in this specific subtype, supporting a watch-and-wait approach.

This comprehensive review outlines evolving frontline MCL strategies, highlighting the integration of targeted agents, re-evaluation of transplant, and the emerging role of MRD-guided therapy to improve outcomes.

This review details intrinsic (NF-κB, apoptosis, DNA repair) and extrinsic (tumor microenvironment) resistance mechanisms, identifying new therapeutic vulnerabilities to guide personalized strategies for high-risk MCL patients.

This review summarizes current and emerging therapies for relapsed/refractory MCL, highlighting key strategies like BTKi/BCL2i combinations, CAR-T, and bispecific antibodies for this poor-prognosis population.

This review synthesizes clinical, molecular, and genomic markers to define high-risk MCL, guiding risk-stratified treatment and highlighting future therapies like bispecifics for this poor-prognosis population.

This editorial introduces a review series on mantle cell lymphoma, framing the rapid evolution of the treatment landscape from chemotherapy to novel targeted and cellular therapies.

This review contextualizes CAR-T therapy's established role in relapsed/refractory MCL, summarizing universal challenges such as toxicity, access, cost, and the need for effective salvage treatments post-progression.

A rare case of extranodal MCL presenting as bilateral adrenal masses showed avidity on both FDG and DOTATATE PET/CT, expanding the differential diagnosis for adrenal lesions.

This review clarifies that cyclin D1-negative MCL is driven by CCND2 or CCND3 translocations, proposing new terminology to improve diagnostic accuracy for this rare and often missed subtype.

An MCL patient on ibrutinib had persistent COVID-19 missed by nasopharyngeal swabs but diagnosed via bronchoalveolar lavage, underscoring the need for deeper sampling in immunosuppressed patients.

Experienced nurses and advanced practice providers outline key considerations for implementing a successful outpatient lisocabtagene maraleucel CAR-T program, offering a practical framework for managing MCL patients.

Real-world data show BTKi refractoriness and poor in-vivo brexu-cel expansion predict worse survival, identifying high-risk patients for early relapse and highlighting CAR-T kinetics as a key biomarker.

This review summarizes how second-generation BTK inhibitors like zanubrutinib offer improved target selectivity and tolerability over first-generation agents, providing a potentially safer therapeutic option for MCL patients.

This review advocates for using prognostic tools like MIPI and TP53 status to guide risk-adapted therapy in MCL, intensifying for high-risk and de-escalating for low-risk patients.

In relapsed/refractory MCL, the phase 3 SYMPATICO trial established ibrutinib plus venetoclax as superior to ibrutinib alone, significantly improving median progression-free survival by nearly 10 months.

Robotic-assisted bronchoscopy offers a safe, minimally invasive method for biopsying hard-to-reach aortopulmonary lymph nodes, as demonstrated in a case confirming MCL recurrence.

A novel Mcl1-degrading AUTAC compound synergizes with proteasome inhibitors by hijacking the adaptive autophagy response, offering a preclinical strategy to overcome proteasome inhibitor resistance in MCL.

In MCL cells, the RNA processing factor NUDT21 undergoes alternative polyadenylation to evade miRNA-mediated suppression, revealing a novel mechanism of gene regulation that could be a future therapeutic target.

The chemotherapy-free BOVen regimen (zanubrutinib, obinutuzumab, venetoclax) shows high efficacy (88% CR) and deep MRD negativity in previously untreated, high-risk TP53-mutated MCL, a historically chemo-refractory population.

This review outlines management strategies for delayed complications of CAR T-cell therapy in MCL, moving beyond acute CRS and ICANS to improve long-term patient care and outcomes.

A real-world Japanese study identified BTK inhibitor-based therapy and length of hospitalization as the main drivers of increased healthcare costs, providing crucial data for health economic planning.

Fixed-duration glofitamab monotherapy achieves high complete response rates (78%) in heavily pretreated relapsed/refractory MCL, including post-BTKi patients, offering a potent new off-the-shelf immunotherapy.

This case report details the management of severe brexu-cel toxicities, including a rare intestinal perforation, and highlights the use of anakinra for ICANS, emphasizing complex toxicity management.

This case report describes a rare MCL relapse presenting as diabetes insipidus due to CNS involvement of the hypothalamus, highlighting an unusual manifestation of extranodal disease.

Preclinical data shows the TKI anlotinib inhibits MCL proliferation by targeting the PI3K/AKT/mTOR pathway and modulates the tumor microenvironment, identifying a potential new oral therapy for MCL.

Rituximab maintenance after bendamustine-based therapy in MCL patients is associated with worse outcomes from SARS-CoV-2 infection, highlighting a significant infectious toxicity risk for this common regimen.

This case report of late, recurrent neurotoxicity after brexucabtagene autoleucel demonstrates a mechanism of direct CNS infiltration by CAR-T cells, highlighting the need for long-term vigilance.

Pirtobrutinib achieves an 81% overall response rate in MCL patients intolerant to prior covalent BTKis, offering a well-tolerated sequential option to maintain effective BTK pathway inhibition.

A novel electrochemical sensor was developed for highly sensitive bortezomib detection, potentially enabling therapeutic drug monitoring to personalize dosing and manage toxicity in MCL patients.

A rare case of MCL transdifferentiating into a clonally-related T-cell lymphoma demonstrates a novel transformation mechanism where B-cell markers are lost, complicating diagnosis at relapse.